LPAR3

Across TCGA pan-cancer cohorts, LPAR3 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated LPAR3 data layer compared with 6 for mutation status.

The strongest signal is observed in mesothelioma (MESO), where higher LPAR3 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LPAR3 expression acts as an unfavorable survival marker, although some lineages such as OV and UVM show a favorable association.

MESO, HNSC, and LGG are the cancer types where LPAR3 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	All	0.417	0.682	.001	46	view →
HNSC	OS	Quartile	III,IV	0.650	0.807	.008	43	view →
LGG	OS	Median	All	0.746	0.868	<.001	37	view →
OV	DFS	Quartile	III,IV	0.390	0.291	.008	36	view →
UVM	DFS	Quartile	All	0.921	0.491	.007	30	view →
STAD	DFS	Quartile	All	0.374	0.547	.009	27	view →
ACC	DFS	Median	II,III,IV	0.659	0.403	.009	24	view →
ESCA	OS	Tertile	All	1.000	0.563	.022	21	view →
SARC	OS	Tertile	All	0.660	0.828	.002	16	view →
LUAD	DFS	Median	II,III,IV	0.403	0.122	.012	16	view →
BLCA	DFS	Median	III,IV	0.359	0.587	.004	15	view →
LAML	DFS	Tertile	All	0.458	0.746	.011	14	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

LPAR3–MESO (OS)

Open the MESO breakdown →